An Interventional Study of Infigratinib in Children With Hypochondroplasia
Enrolling by invitation · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Hypochondroplasia
In brief
ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib at one of two doses, who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).
Key facts
- Study ID
- NCT06873035
- Run by
- QED Therapeutics, a BridgeBio company
- People needed
- 24
- Starts
- 2025-04-22
- Expected to finish
- 2027-01-01
- Last updated by the study team
- 2026-07-16
Who can join
Age: 3 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Benioff Children's Hospital — Oakland, California, United States
- Childrens Hospital Colorado — Aurora, Colorado, United States
- Children's National Hospital — Washington D.C., District of Columbia, United States
- Johns Hopkins School of Medicine — Baltimore, Maryland, United States
- University of Missouri — Columbia, Missouri, United States
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
- University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic — Madison, Wisconsin, United States
- Murdoch Children's Research Institute - The Royal Children's Hospital Melbourne — Parkville, Victoria, Australia
- London Health Services Centre - Children's Hospital of Western Ontario — London, Ontario, Canada
- Children's Hospital of Eastern Ontario Research Institute — Ottawa, Ontario, Canada
- Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine — Montreal, Quebec, Canada
- Hôpital Femme Mère Enfant — Bron, France, France
- Hôpital Universitaire Necker-Enfants Malades — Paris, France, France
- Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants — Toulouse, France, France
- Haukeland University Hospital — Bergen, Norway, Norway
- Paediatric Clinical Research Unit at Oslo University Hospital — Oslo, Norway, Norway
- Hospital Pediátrico de Coimbra — Coimbra, Portugal, Portugal
- KK Women's and Children's Hospital — Singapore, Singapore, Singapore
- Unidad de Cirugía Artroscopica, Hopsital MIKS — Vitoria-Gasteiz, Spain, Spain
- Astrid Lindgren Children's Hospital — Solna, Sweden, Sweden
- Manchester University — Manchester, England, United Kingdom
- Sheffield Children's Hospital — Sheffield, England, United Kingdom
- Glasgow Clinical Research Facility, Queen Elizabeth University Hospital — Glasgow, Scotland, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.